bausch health companies inc glp-1 receptor agonist medications Market Size & Analysis, 2026-2033 Michael Goettler Resigns from Bausch

If validated in adequately powered human trials, this would be a genuinely new mechanism for substance use disorders, rooted in metabolic signalling rather than monoamine modulation

Risk of blindness among patients with diabetes and newly diagnosed diabetic retinopathy

Conclusions and Relevance GLP-1 RA therapy in IIH is associated with significant reductions in medication use, symptoms/signs, and procedural interventions, suggesting its potential as a management strategy

Incretin-based multi-agonist peptides are neuroprotective and anti-inflammatory in cellular models of neurodegeneration

Same syringe reading, completely different point in your protocol

Weight-loss drug targets fat that endangers heart According to a study published by UTSW preventive cardiologist Parag Joshi, M.D., a once-daily dose of liraglutide combined with lifestyle interventions significantly lowered two types of fat that endanger heart health